InflaRx NV
NASDAQ:IFRX

Watchlist Manager
InflaRx NV Logo
InflaRx NV
NASDAQ:IFRX
Watchlist
Price: 2.5 USD 11.61% Market Closed
Market Cap: 147.2m USD
Have any thoughts about
InflaRx NV?
Write Note

InflaRx NV
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

InflaRx NV
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
InflaRx NV
NASDAQ:IFRX
Accounts Payable
€11.7m
CAGR 3-Years
1%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Accounts Payable
€354m
CAGR 3-Years
51%
CAGR 5-Years
53%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Accounts Payable
€72.6m
CAGR 3-Years
-16%
CAGR 5-Years
11%
CAGR 10-Years
20%
Immatics NV
NASDAQ:IMTX
Accounts Payable
€7.7m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Accounts Payable
€58.1m
CAGR 3-Years
23%
CAGR 5-Years
8%
CAGR 10-Years
1%
Formycon AG
XETRA:FYB
Accounts Payable
€16.3m
CAGR 3-Years
46%
CAGR 5-Years
43%
CAGR 10-Years
N/A
No Stocks Found

InflaRx NV
Glance View

Market Cap
147.2m USD
Industry
Biotechnology

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

IFRX Intrinsic Value
1.95 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is InflaRx NV's Accounts Payable?
Accounts Payable
11.7m EUR

Based on the financial report for Sep 30, 2024, InflaRx NV's Accounts Payable amounts to 11.7m EUR.

What is InflaRx NV's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-7%

Over the last year, the Accounts Payable growth was 95%. The average annual Accounts Payable growth rates for InflaRx NV have been 1% over the past three years , -7% over the past five years .

Back to Top